Incyte Corp (INCY)

Mar 31, 2025, 5:02 PM EDT - 2 days ago

These 20 worst-performing stocks in the S&P 500 sank 17% or more in March

DAL BBY CCL CEG CZR DECK DXCM

Mar 26, 2025, 7:30 AM EDT - 7 days ago

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

Mar 18, 2025, 3:39 PM EDT - 15 days ago

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Mar 17, 2025, 12:30 PM EDT - 16 days ago

Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results

Mar 17, 2025, 11:21 AM EDT - 16 days ago

Incyte Is Today's Worst S&P 500 Stock. Here's Why.

Mar 17, 2025, 9:53 AM EDT - 16 days ago

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

Mar 17, 2025, 8:58 AM EDT - 16 days ago

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

TSLA

Mar 17, 2025, 7:10 AM EDT - 16 days ago

Incyte's skin disease drug meets main goal in two late-stage studies

Mar 17, 2025, 7:00 AM EDT - 16 days ago

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

Mar 8, 2025, 1:00 PM EST - 25 days ago

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

LLY

Mar 8, 2025, 9:01 AM EST - 25 days ago

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Mar 7, 2025, 4:30 PM EST - 26 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 28, 2025, 9:30 AM EST - 4 weeks ago

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Feb 20, 2025, 8:00 AM EST - 5 weeks ago

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Feb 18, 2025, 8:00 AM EST - 6 weeks ago

Incyte to Present at Upcoming Investor Conferences

Feb 12, 2025, 8:30 AM EST - 7 weeks ago

Reevaluating Incyte Corporation After Earnings (Technical Analysis)

Feb 11, 2025, 7:30 AM EST - 7 weeks ago

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Feb 10, 2025, 11:52 AM EST - 7 weeks ago

Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript

Feb 10, 2025, 8:38 AM EST - 7 weeks ago

Incyte reports quarterly sales above estimates on strong demand for key drugs

Feb 10, 2025, 7:00 AM EST - 7 weeks ago

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Jan 21, 2025, 8:00 AM EST - 2 months ago

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

Jan 15, 2025, 5:34 PM EST - 2 months ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

SNDX

Jan 13, 2025, 6:10 PM EST - 2 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 13, 2025, 8:30 AM EST - 2 months ago

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 11, 2025, 9:30 AM EST - 2 months ago

Incyte: Multiple Drug Launches Bode Well For Future Growth

Dec 17, 2024, 8:00 AM EST - 3 months ago

Incyte to Present at Upcoming Investor Conference

Dec 10, 2024, 10:30 AM EST - 4 months ago

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

Dec 7, 2024, 7:30 AM EST - 4 months ago

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Nov 26, 2024, 4:10 PM EST - 4 months ago

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Nov 25, 2024, 10:09 AM EST - 4 months ago

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Nov 19, 2024, 12:51 PM EST - 4 months ago

Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study

Nov 19, 2024, 12:21 PM EST - 4 months ago

Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock.

Nov 19, 2024, 12:18 PM EST - 4 months ago

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges

Nov 18, 2024, 4:30 PM EST - 4 months ago

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Oct 31, 2024, 7:41 AM EDT - 5 months ago

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 30, 2024, 4:37 PM EDT - 5 months ago

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock